Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

domes pharma, 3 rue andré citroën, 63430 pont du château, francuska - kalijev bromid - tableta - pasa

Europska Unija - hrvatski - EMA (European Medicines Agency)

covis pharma europe b.v. - aclidinium bromide - plućna bolest, kronična opstruktivna - lijekovi za opstruktivne plućne bolesti dišnih putova, - bretaris genuair je označen kao liječenje bronhodilatatora za održavanje kako bi se uklonili simptomi kod odraslih osoba s kroničnom opstruktivnom plućnom bolesti (copd).

Europska Unija - hrvatski - EMA (European Medicines Agency)

covis pharma europe b.v. - aclidinium bromide - plućna bolest, kronična opstruktivna - lijekovi za opstruktivne plućne bolesti dišnih putova, - farmakovigilancije genuair je indiciran kao bronhodilatacijska terapija održavanja za ublažavanje simptoma u odraslih bolesnika s kroničnom opstruktivnom plućnom bolesti (kopb).

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - plućna bolest, kronična opstruktivna - lijekovi za opstruktivne plućne bolesti dišnih putova, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Europska Unija - hrvatski - EMA (European Medicines Agency)

jenson pharmaceutical services limited - dextromethorphan, kinidin - neuronske manifestacije - ostali lijekovi protiv živčanog sustava - nuedexta je indiciran za simptomatsko liječenje pseudobulbarskih učinaka (pba) u odraslih osoba. učinkovitost je ispitivana samo u bolesnika s temeljnom amiloidnom lateralnom sklerozom ili multipla sklerozom.

Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - Талидомид - multipli mijelom - imunosupresivi - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Europska Unija - hrvatski - EMA (European Medicines Agency)

covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - plućna bolest, kronična opstruktivna - lijekovi za opstruktivne plućne bolesti dišnih putova, - brimica genuair navodi kao terapiju održavanja бронходилататор za opstrukcije dišnih organa i ublažavanje simptoma kod odraslih bolesnika s kroničnom opstruktivnom plućnom bolesti (kopb).

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - plućna bolest, kronična opstruktivna - lijekovi za opstruktivne plućne bolesti dišnih putova, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.